4investors | Börsen-News | Adhoc- und Unternehmensnews | 4SC

DGAP-News: 4SC AG: 4 upcoming conferences

Bild und Copyright: 4SC.

Bild und Copyright: 4SC.

16.05.2019 (www.4investors.de - in Kooperation mit DGAP - EQS Group):


DGAP-News: 4SC AG / Key word(s): Conference

4SC AG: 4 upcoming conferences
16.05.2019 / 07:30


The issuer is solely responsible for the content of this announcement.
4SC AG: 4 upcoming conferences

Planegg-Martinsried, Germany, 16 May 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation in upcoming financial and scientific conferences. 4SC's management and scientists will be available for one-on-one meetings at these events.

20th Annual BioEquity Europe

20 - 21 May 2019
Barcelona, Spain

ASCO 2019

31 May - 4 June 2019
Chicago, USA

Raymond James Life Sciences and MedTech Conference

18 - 19 June 2019
New York, USA

9th European Post-Chicago Melanoma / Skin Cancer Meeting

20 - 21 June 2019
Munich, Germany

- Announcement ends -

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

4SC
Anna Niedl, Ph.D., CIRO
Corporate Communications & Investor Relationsanna.niedl@4sc.com
+49 89 700763-66

LifeSci Advisors
Hans Herklots
Managing Directorhherklots@lifesciadvisors.com
+41 79 598 7149












16.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
4SC AG

Fraunhoferstr. 22

82152 Planegg-Martinsried


Germany
Phone:
+49 89 700763-0
Fax:
+49 89 700763-29
E-mail:
public@4sc.com
Internet:
www.4sc.com
ISIN:
DE000A14KL72
WKN:
A14KL7
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
811759

 
End of News
DGAP News Service




811759  16.05.2019 



Weitere DGAP-News von 4SC

28.08.2019 - DGAP-News: 4SC AG: 8 anstehende Konferenzen
13.08.2019 - DGAP-News: 4SC AG erhält Meilensteinzahlung von Link Health - Link Health startet klinische Phase-I-Studie mit LH031 (4SC-205) in fortgeschrittenen soliden Tumoren oder Lymphomen
08.08.2019 - DGAP-News: 4SC AG informiert über Q2 und 6M 2019
01.08.2019 - DGAP-News: 4SC AG: Telefonkonferenz am 8. August 2019 zum Halbjahresbericht 2019
25.07.2019 - DGAP-News: 4SC AG: Positive Sicherheitsdaten aus Phase-Ib/II-Studie EMERGE mit Domatinostat + Avelumab im Magen-Darm-Krebs

4investors-News zu 4SC

13.08.2019 - 4SC: Millionen-Zahlung von Link Health
08.08.2019 - 4SC senkt Halbjahresverlust - Umsatz sinkt
01.08.2019 - 4SC Aktie: Was ist denn hier los?
25.07.2019 - 4SC: News aus der Studie mit Domatinostat
11.07.2019 - 4SC erweitert Studienprogramm für Domatinostat